APTOF official logo APTOF
APTOF 1-star rating from Upturn Advisory
DMD Digital Health Connections Group Inc (APTOF) company logo

DMD Digital Health Connections Group Inc (APTOF)

DMD Digital Health Connections Group Inc (APTOF) 1-star rating from Upturn Advisory
$1.54
Last Close (24-hour delay)
Profit since last BUY15.79%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 34 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/18/2025: APTOF (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $12.5

1 Year Target Price $12.5

Analysts Price Target For last 52 week
$12.5 Target price
52w Low $0.64
Current$1.54
52w High $8.1

Analysis of Past Performance

Type Stock
Historic Profit 15.79%
Avg. Invested days 34
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 5.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.03M USD
Price to earnings Ratio 2.29
1Y Target Price 12.5
Price to earnings Ratio 2.29
1Y Target Price 12.5
Volume (30-day avg) 1
Beta 0.59
52 Weeks Range 0.64 - 8.10
Updated Date 12/19/2025
52 Weeks Range 0.64 - 8.10
Updated Date 12/19/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.69

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -141.01%
Return on Equity (TTM) -

Valuation

Trailing PE 2.29
Forward PE -
Enterprise Value 22384847
Price to Sales(TTM) -
Enterprise Value 22384847
Price to Sales(TTM) -
Enterprise Value to Revenue 0.9
Enterprise Value to EBITDA 0.05
Shares Outstanding 2552429
Shares Floating 2035664
Shares Outstanding 2552429
Shares Floating 2035664
Percent Insiders 20.25
Percent Institutions 3.91

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

DMD Digital Health Connections Group Inc

DMD Digital Health Connections Group Inc(APTOF) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

DMD Digital Health Connections Group Inc. (DMD) is a digital health company focused on providing solutions for healthcare professionals. While specific founding year and detailed historical milestones are not readily available in public domain, the company has evolved to offer a suite of digital tools aimed at improving healthcare delivery and patient engagement. Its development has been shaped by the increasing digitization within the healthcare sector.

Company business area logo Core Business Areas

  • Provider Engagement Solutions: DMD offers platforms and services designed to connect pharmaceutical and life sciences companies with healthcare providers. This includes tools for targeted outreach, data analytics, and communication, facilitating the dissemination of critical medical information and product updates to physicians.
  • Data & Analytics Services: The company provides data analytics solutions that help clients understand physician behavior, market trends, and the effectiveness of their outreach programs. This data-driven approach aims to optimize engagement strategies.
  • Digital Marketing and Communications: DMD leverages digital channels to support marketing and communication efforts for its clients in the healthcare industry, enabling them to reach and engage with healthcare professionals through various digital touchpoints.

leadership logo Leadership and Structure

Information on DMD Digital Health Connections Group Inc.'s specific leadership team and detailed organizational structure is not extensively published. As a privately held entity or a smaller public company, its leadership may be more concentrated and less publicly visible than that of larger corporations.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • Provider Engagement Platform: DMD's core offering is likely a platform that enables pharmaceutical and medical device companies to engage with physicians. This platform would provide functionalities for personalized messaging, data analysis of physician interactions, and compliance management. Specific market share data, number of users, or revenue attribution to this product is not publicly disclosed. Competitors in this space include companies that offer similar CRM, data analytics, and engagement solutions for the life sciences industry, such as Veeva Systems, IQVIA, and smaller niche providers.
  • Physician Data & Analytics: This service likely provides deep insights into physician prescribing habits, professional affiliations, and engagement patterns. This data is crucial for targeted marketing and strategic planning for life sciences companies. Market share is difficult to ascertain without specific product names and revenue breakdowns. Competitors include large data providers like IQVIA, Definitive Healthcare, and other healthcare analytics firms.

Market Dynamics

industry overview logo Industry Overview

The digital health market is rapidly expanding, driven by technological advancements, increasing adoption of electronic health records, and a growing demand for personalized patient care and efficient provider engagement. The pharmaceutical and life sciences sector is increasingly investing in digital solutions to improve their go-to-market strategies and physician outreach.

Positioning

DMD Digital Health Connections Group Inc. is positioned as a specialized provider of digital engagement and data analytics solutions for the life sciences industry. Its competitive advantage likely lies in its focused approach to connecting pharmaceutical/biotech companies with healthcare professionals, potentially offering tailored data insights and communication tools.

Total Addressable Market (TAM)

The TAM for digital health solutions, particularly those serving the life sciences sector for provider engagement and data analytics, is substantial and growing. It encompasses a multi-billion dollar market globally. DMD's positioning within this TAM is as a niche player focused on a specific segment, aiming to capture a portion of the spend by life sciences companies on commercial operations and marketing.

Upturn SWOT Analysis

Strengths

  • Specialized focus on healthcare provider engagement.
  • Potential for proprietary data and analytics capabilities.
  • Agility and responsiveness as a potentially smaller entity.

Weaknesses

  • Limited public information on financial performance and market traction.
  • Brand recognition might be lower compared to larger industry players.
  • Dependence on a specific industry segment (life sciences).
  • Potential challenges in scaling operations without significant investment.

Opportunities

  • Increasing adoption of digital tools by pharmaceutical companies.
  • Growing demand for data-driven insights in healthcare marketing.
  • Expansion into new therapeutic areas or geographical markets.
  • Partnerships with EMR/EHR providers or other health tech companies.

Threats

  • Intense competition from established and emerging digital health companies.
  • Evolving regulatory landscape for data privacy and healthcare marketing.
  • Consolidation within the life sciences and digital health industries.
  • Changes in pharmaceutical marketing budgets or strategies.

Competitors and Market Share

Key competitor logo Key Competitors

  • Veeva Systems (VEEV)
  • IQVIA Holdings Inc. (IQV)
  • Definitive Healthcare Corp. (DH)

Competitive Landscape

DMD Digital Health Connections Group Inc. operates in a competitive landscape dominated by larger, well-established players with extensive resources. Its advantages may lie in its agility and ability to provide highly specialized solutions for niche needs within provider engagement. However, it faces challenges in matching the scale, breadth of services, and marketing power of its larger competitors.

Growth Trajectory and Initiatives

Historical Growth: Information on the historical growth of DMD Digital Health Connections Group Inc. is not publicly disclosed. Its growth would likely be tied to the adoption of digital solutions within the pharmaceutical and life sciences sectors.

Future Projections: Specific future growth projections for DMD Digital Health Connections Group Inc. are not publicly available. Any projections would be speculative based on industry trends and the company's potential market penetration.

Recent Initiatives: Specific recent strategic initiatives undertaken by DMD Digital Health Connections Group Inc. are not widely publicized. These could include new product developments, strategic partnerships, or expansion into new market segments.

Summary

DMD Digital Health Connections Group Inc. operates in the growing digital health sector, focusing on provider engagement solutions for the life sciences industry. While its specialized approach may offer unique value, the lack of public financial data makes a thorough assessment difficult. The company faces significant competition from larger players with established market positions. Its success will likely depend on its ability to innovate, secure strategic partnerships, and demonstrate tangible ROI to its clients in a dynamic and regulated industry.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • General industry knowledge of the digital health and life sciences sectors.
  • Hypothetical positioning based on typical offerings of companies in this space.
  • Publicly available information on competitor companies.

Disclaimers:

This JSON output is based on the limited publicly available information for DMD Digital Health Connections Group Inc. It is not an exhaustive analysis and should not be considered investment advice. Financial performance, leadership, specific product details, and market share are not fully disclosed and therefore speculative. Investors should conduct their own thorough due diligence.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About DMD Digital Health Connections Group Inc

Exchange NASDAQ
Headquaters Toronto, ON, Canada
IPO Launch date 2014-10-23
Chairman, President & CEO Dr. William G. Rice Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.